Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, November 22, 2014
Technology Networks
 
Register | Sign in
Home Page>News

  News Archive

Genticel Completes Procervix Phase II Study Enrollment Ahead of Schedule
Saturday, November 15, 2014
A total of 239 subjects infected with HPV 16 and/or 18 enrolled at 39 clinical centers throughout Europe for RHEIA-VAC study of ProCervix.

GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey
Friday, November 14, 2014
Supports Turkey’s ambitions to expand domestic biopharmaceutical industry. Laboratory will be a key component of GE’s new Innovation Center in Istanbul.

Large-scale Study Raises Hopes For Development Of E. coli Vaccine
Wednesday, November 12, 2014
Global comparison reveals surprisingly close relation between E. coli strains that cause traveller's diarrhoea.

Typhoid Gene Unravelled
Tuesday, November 11, 2014
Natural resistance against typhoid fever is linked to a particular form of the HLA-DRB1 gene.

Making Vaccines More Effective In The Elderly
Tuesday, November 11, 2014
Compound shown to restore the immune system’s inbuilt memory.

Developing Lifesaving Vaccines in a New Way
Monday, November 10, 2014
Rutgers-led immune system research also may help reveal new asthma clues.

New Vaccine Generates Strong Immune Response Against Hepatitis C
Friday, November 07, 2014
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.

Inhaled Ebola Vaccine May Offer Long-Term Protection from Virus
Friday, November 07, 2014
A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus.

Immune Booster Helps Improve Survival In Metastatic Melanoma
Thursday, November 06, 2014
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant.

<< 1 2 3 4 5 6 7 >>
Showing Results 11 - 20 of 1165
Skyscraper Banner
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv